JP2024543214A5 - - Google Patents

Info

Publication number
JP2024543214A5
JP2024543214A5 JP2024532831A JP2024532831A JP2024543214A5 JP 2024543214 A5 JP2024543214 A5 JP 2024543214A5 JP 2024532831 A JP2024532831 A JP 2024532831A JP 2024532831 A JP2024532831 A JP 2024532831A JP 2024543214 A5 JP2024543214 A5 JP 2024543214A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
linkage
inventions
spacer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543214A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/051713 external-priority patent/WO2023102225A2/en
Publication of JP2024543214A publication Critical patent/JP2024543214A/ja
Publication of JP2024543214A5 publication Critical patent/JP2024543214A5/ja
Pending legal-status Critical Current

Links

JP2024532831A 2021-12-03 2022-12-02 Ｕｎｃ１３ａ遺伝子転写物のモジュレーターを使用する神経疾患の処置 Pending JP2024543214A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163285786P 2021-12-03 2021-12-03
US63/285,786 2021-12-03
US202263350206P 2022-06-08 2022-06-08
US63/350,206 2022-06-08
US202263398987P 2022-08-18 2022-08-18
US63/398,987 2022-08-18
PCT/US2022/051713 WO2023102225A2 (en) 2021-12-03 2022-12-02 Treatment of neurological diseases using modulators of unc13a gene transcripts

Publications (2)

Publication Number Publication Date
JP2024543214A JP2024543214A (ja) 2024-11-19
JP2024543214A5 true JP2024543214A5 (https=) 2025-12-10

Family

ID=86613080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532831A Pending JP2024543214A (ja) 2021-12-03 2022-12-02 Ｕｎｃ１３ａ遺伝子転写物のモジュレーターを使用する神経疾患の処置

Country Status (16)

Country Link
US (1) US20250051766A1 (https=)
EP (1) EP4441225A4 (https=)
JP (1) JP2024543214A (https=)
KR (1) KR20240129627A9 (https=)
CN (1) CN119790152A (https=)
AU (1) AU2022400851A1 (https=)
CA (1) CA3239482A1 (https=)
CL (1) CL2024001657A1 (https=)
CO (1) CO2024008076A2 (https=)
CR (1) CR20240269A (https=)
DO (1) DOP2024000107A (https=)
IL (1) IL313203A (https=)
JO (1) JOP20240125A1 (https=)
MX (1) MX2024006763A (https=)
PE (1) PE20250677A1 (https=)
WO (1) WO2023102225A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
AU2023356317A1 (en) * 2022-10-05 2025-05-15 Trace Neuroscience, Inc. Unc13a antisense oligonucleotides and uses thereof
WO2024178223A1 (en) * 2023-02-24 2024-08-29 Northwestern University Antisense oligonucleotides for preventing unc13a misplicing
US12612630B2 (en) 2024-03-05 2026-04-28 Takeda Pharmaceutical Company Limited Compositions and methods for splicing modulation of UNC13A
WO2025255388A1 (en) * 2024-06-05 2025-12-11 Camp4 Therapeutics Corporation Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2026080323A1 (en) 2024-10-09 2026-04-16 Quralis Corporation Treatment of neurological diseases using modulators of unc13a gene transcripts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1470423A2 (en) * 2001-11-05 2004-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Unc-13 in the modulation of neurotransmission and secretion events
EP2831232A4 (en) * 2012-03-30 2015-11-04 Univ Washington METHOD FOR MODULATING TAU EXPRESSION TO REDUCE PROBLEMS AND MODIFY A NEURODEGENERATIVE SYNDROME
ES2788426T3 (es) * 2014-06-16 2020-10-21 Univ Johns Hopkins Composiciones y métodos para la expresión de ARNs de guía de CRISPR utilizando el promotor de H1
US20220008368A1 (en) * 2018-11-15 2022-01-13 President And Fellows Of Harvard College Methods and compositions related to targeting ffar2 and ilc3 populations for the treatment of a gastrointestinal disease
EP4320236A1 (en) * 2021-04-06 2024-02-14 Maze Therapeutics, Inc. Compositions and methods for treating tdp-43 proteinopathy

Similar Documents

Publication Publication Date Title
JP2024543214A5 (https=)
JP2022536085A5 (https=)
US20250051766A1 (en) Treatment of neurological diseases using modulators of unc13a gene transcripts
JP2009067805A (ja) 中枢神経系へのポリヌクレオチド薬剤の送達
JP2018528783A5 (https=)
JP2014507143A (ja) アンチセンスオリゴヌクレオチド
EP3765476B1 (en) Modified oligonucleotides for use in treatment of tauopathies
TWI870557B (zh) 用於調節ｓｍｎ２之化合物及方法
JP2023536472A5 (https=)
EP4441226A2 (en) Splice switcher antisense oligonucleotides with modified backbone chemistries
JP2024545052A5 (https=)
JP2025500335A5 (https=)
IL313205A (en) Microbial consortia
JP2024540537A5 (https=)
JP2023528435A5 (https=)
JP2025501682A5 (https=)
US20230374519A1 (en) Compounds and methods for modulating pmp22
RU2024118442A (ru) Лечение неврологических заболеваний с применением модуляторов транскриптов гена unc13a
JP2025513757A5 (https=)
US20240368591A1 (en) Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
RU2025125558A (ru) Способы лечения нарушений нервной системы
RU2021138237A (ru) Олигонуклеотиды и способы применения для лечения неврологических заболеваний
EA053024B1 (ru) Антисмысловые олигонуклеотиды-переключатели сплайсинга с модифицированной химией скелета
HK40121031A (zh) 具有经修饰的主链化学的剪接转换器反义寡核苷酸
CN121986163A (en) Modified UNC13A oligonucleotides